Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/223453
Title: Biosimilars and reference biological medicines in the treatment of rheumatoid arthritis: A multicenter cross-sectional study in Catalonia, Spain.
Author: Mas Marín, Joan
Molina-Olano, Marina
Rudi Sola, Nuria
Miserachs Aranda, Nuria
Montoliu-Alcón, Paula
De Pourcq, Jan Thomas
Quiñones, Carles
Borràs-Trias, Laura
Fernández-Cañabate, Eva
González-Valdivieso, Juan
Figueiredo Escribá, Carlos de
Delgado Hernández, René
Braza Reyes, Antonio J.
Fernández Lastra, Cecilia
Mariño Hernández, Eduardo L.
Modamio Charles, Pilar
Keywords: Reumatisme
Terapèutica
Artritis reumatoide
Rheumatism
Therapeutics
Rheumatoid arthritis
Issue Date: 3-Jul-2025
Publisher: Springer Verlag
Abstract: Objective</strong> The objective of this study is to compare the effectiveness of reference biologic medicines used in the treatmentof rheumatoid arthritis (RA) specifically adalimumab, etanercept, and infliximab, with corresponding biosimilar medicines,based on an exploratory analysis of clinical data obtained in patients treated with these medicines in five hospitals in theregion of Catalonia, Spain.<strong>Methods</strong> There is a consultation of the database of the Registry of Patients and Treatments of the Catalan Health Service:extraction of data from adult patients diagnosed with moderate and severe active RA and with active prescription of at leastone biological drug (reference or biosimilar) or JAK inhibitor. To compare the effectiveness of each reference biologic withits biosimilar, differences in mean DAS28-ESR values before and after treatment were assessed for adalimumab and itsbiosimilar, etanercept and its biosimilar, and infliximab and its biosimilar.<strong>Results</strong> The study consisted of 643 patients. The most dispensed medicines were anti-TNFs, with 303 patients on treatment. Thirty-sixpercent of all patients were using biosimilars. No statistically significant differences were observed in any of the three comparisonsbetween the reference biologic medicine and its biosimilar. These findings suggest that biosimilars have comparable effectiveness toreference biologics in reducing DAS28-ESR; in addition, they can provide substantial savings to public health systems.<strong>Conclusions</strong> A significant number of patients diagnosed with moderate to severe active RA were treated with biologicalmedicines and receiving the available biosimilar treatments. Future research should be conducted to confirm comparableeffectiveness found to their reference biologic medicines in this exploratory analysis.
Note: Reproducció del document publicat a: https://doi.org/https://doi.org/10.1007/s10067-025-07568-9
It is part of: Clinical Rheumatology, 2025
URI: https://hdl.handle.net/2445/223453
Related resource: https://doi.org/https://doi.org/10.1007/s10067-025-07568-9
ISSN: 0770-3198
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
896342.pdf1.63 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons